Foscarbidopa/foslevodopa
Combination drug for Parkinson's disease
Foscarbidopa/foslevodopa is a combination medication used in the treatment of Parkinson's disease. It consists of two active components: foscarbidopa and foslevodopa. This combination is designed to improve the delivery and effectiveness of levodopa, a precursor to the neurotransmitter dopamine, which is deficient in patients with Parkinson's disease.
Mechanism of Action[edit | edit source]
Foscarbidopa/foslevodopa works by enhancing the availability of levodopa in the brain. Levodopa is converted to dopamine in the brain, which helps alleviate the symptoms of Parkinson's disease such as tremors, stiffness, and slowness of movement.
Foscarbidopa[edit | edit source]
Foscarbidopa is a prodrug of carbidopa. It acts as a peripheral decarboxylase inhibitor, preventing the conversion of levodopa to dopamine outside the brain. This ensures that more levodopa reaches the central nervous system, where it can be converted to dopamine.
Foslevodopa[edit | edit source]
Foslevodopa is a prodrug of levodopa. It is designed to improve the pharmacokinetic properties of levodopa, allowing for better absorption and bioavailability. Once in the body, foslevodopa is converted to levodopa, which then crosses the blood-brain barrier to be converted into dopamine.
Clinical Use[edit | edit source]
Foscarbidopa/foslevodopa is primarily used in the management of Parkinson's disease. It is particularly beneficial for patients who experience fluctuations in the effectiveness of standard levodopa therapy, known as "on-off" phenomena. By improving the delivery of levodopa, this combination can provide more consistent symptom control.
Administration[edit | edit source]
The medication is typically administered orally. The dosage and frequency depend on the individual patient's needs and response to therapy. It is important for patients to follow their healthcare provider's instructions carefully to optimize treatment outcomes.
Side Effects[edit | edit source]
Common side effects of foscarbidopa/foslevodopa include nausea, dizziness, and headache. As with any medication, there is a risk of more serious side effects, and patients should be monitored for any adverse reactions.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
